LIBTAYO (cemiplimab-rwlc) is a prescription medicine used to treat adults with NSCLC. LIBTAYO may be used alone as a first treatment option when your lung cancer has not spread outside your chest ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Dr. Sleeman has more than two decades of experience as an R&D leader and scientist in inflammatory disease and cancer. His career has encompassed the research and development of six FDA-approved ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

Just like the brand’s logo, the brand’s name is full of meaning, too. In an Instagram video, Meghan explained, “As Ever essentially means ‘as it’s always been,’ and if you’ve ...

CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...